Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $50
Sionna Therapeutics +3.66% Post
Sionna Therapeutics SION | 43.30 43.30 | +3.66% 0.00% Post |
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:
SION) with a Buy and raises the price target from $45 to $50.